BOSTON — Patients with eczema are increasingly turning to over-the-counter cannabinoid products and physicians should be ready to discuss their benefits, according to a poster presented at the American Academy of Dermatology Annual Meeting.
“Current research supports the potential for targeting the cutaneous endocannabinoid system to treat eczematous dermatoses,” Cleo Whiting, BA, of George Washington University, and colleagues wrote. “Our understanding of patient knowledge and utilization of cannabis/cannabis-derived products as treatments for eczema is limited.”